The
current gold standard of 1st line platinum/taxane doublet chemotherapy,
is more tailored towards HGSOC and generally ineffective for mEOC
Mucinous ovarian cancer represents approximately 3% of epithelial
ovarian cancers (EOC). Despite this seemingly low prevalence, it remains
a diagnostic and therapeutic conundrum that has resulted in numerous
attempts to adopt novel strategies in managing this disease.
Anecdotally, there has been a prevailing notion that established gold
standard systemic regimens should be substituted for those utilised in
cancers such as gastrointestinal (GI) malignancies; tumours that share
more biological similarities than other EOC subtypes. This review
summarises the plethora of small studies which have adopted this
philosophy and influenced the design of the multinational GOG142 study,
which was ultimately terminated due to poor accrual. To date, there is a
paucity of evidence to support delivering ‘GI style’ chemotherapy for
mucinous ovarian cancer over and above carboplatin-paclitaxel doublet
therapy. Hence there is an urge to develop studies focused on targeted
therapeutic agents driven by refined mutational analysis and conducted
within the context of harmonised international collaborations.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.